How can sex hormone‑binding globulin (SHBG) be lowered in postmenopausal women receiving subcutaneous testosterone pellets who present with low total testosterone levels?

Measure Free Testosterone and Address Underlying Causes of Elevated SHBG

In postmenopausal women on subcutaneous testosterone pellets presenting with low total testosterone, the priority is to measure free or bioavailable testosterone rather than attempting to lower SHBG, as total testosterone may be misleadingly low while bioactive testosterone remains adequate. If free testosterone is truly low despite pellet therapy, the pellet dose should be adjusted—but pellets themselves are problematic and should be avoided entirely.

Understanding the SHBG-Testosterone Relationship

SHBG binds testosterone with high affinity, reducing the bioavailable fraction that can enter cells and exert androgenic effects 1. When SHBG is elevated, total testosterone appears low even when free (bioactive) testosterone may be normal 2. This is particularly relevant in the first 3-9 months of testosterone treatment in biological women, where total testosterone levels may appear high while free testosterone remains normal due to elevated SHBG 2.

The critical clinical point: Low total testosterone with elevated SHBG does not necessarily indicate androgen deficiency. Free or bioavailable testosterone is the more accurate measure of androgenic status 1.

Diagnostic Approach

Measure What Matters

• Calculate free testosterone from total testosterone, SHBG, and albumin concentrations using validated equations, or measure it directly via equilibrium dialysis 3, 4
• Direct immunoassays for free testosterone are unreliable and should not be used 4
• Liquid chromatography-tandem mass spectrometry provides the most accurate total testosterone measurement in women 4, 5

Identify Causes of Elevated SHBG

SHBG increases with 6, 3:

• Aging (common in postmenopausal women)
• Estrogen therapy (oral estrogens have greater effect than transdermal)
• Hyperthyroidism
• Hepatic disease
• HIV/AIDS
• Certain medications (anticonvulsants, thyroid hormone)

SHBG decreases with 6, 3:

• Obesity (most clinically relevant modifiable factor)
• Insulin resistance/metabolic syndrome/type 2 diabetes
• Hypothyroidism
• Exogenous testosterone, glucocorticoids, growth hormone
• Cushing's disease, acromegaly
• Nonalcoholic fatty liver disease

Management Strategy

If Free Testosterone is Adequate

Stop here. The patient does not have androgen deficiency despite low total testosterone. No intervention to lower SHBG is needed or recommended.

If Free Testosterone is Truly Low

1. Discontinue testosterone pellets immediately 7

   • Pellets produce supraphysiologic testosterone concentrations
   • They are explicitly not recommended for women due to inability to titrate dosing and safety concerns 7
   • The global consensus statement on testosterone therapy for women specifically advises against pellet use 7

2. Address modifiable causes of elevated SHBG:

   • Weight reduction if obese: Obesity suppresses SHBG; weight loss increases SHBG but improves insulin sensitivity, which may paradoxically improve free testosterone availability 8
   • Evaluate for hyperthyroidism: Check TSH and free T4
   • Review medications: Discontinue or substitute drugs that increase SHBG if possible
   • Screen for liver disease: Check liver function tests
   • Assess for insulin resistance: Fasting glucose, insulin, HbA1c 8, 9

3. If testosterone replacement is indicated (only for hypoactive sexual desire disorder after formal biopsychosocial assessment 7):

   • Use physiologic dosing with transdermal preparations (not approved male formulations used off-label at appropriate doses)
   • Target testosterone levels in the physiologic premenopausal female range
   • Measure baseline total testosterone before starting
   • Recheck at 3-6 weeks, then every 6 months 7
   • Discontinue if no benefit by 6 months 7

Critical Pitfalls to Avoid

• Do not chase total testosterone levels in isolation—this leads to overdosing and virilization
• Do not use compounded "bioidentical" preparations unless no approved product exists, and only from pharmacies meeting Good Manufacturing Practice standards 7
• Do not attempt to pharmacologically suppress SHBG—this is not a therapeutic target and may worsen metabolic health
• Do not continue pellet therapy—the inability to adjust dosing and risk of supraphysiologic levels make pellets inappropriate for women 7

The Paradox of SHBG in Postmenopausal Women

Research shows SHBG levels may actually increase in postmenopause despite declining estrogen 10, 9, and higher SHBG correlates with lower free testosterone and increased urgency urinary incontinence 11. However, the relationship between SHBG and testosterone differs fundamentally between endogenous production and exogenous administration 12. In men receiving transdermal testosterone, SHBG levels show no correlation with total testosterone—suggesting exogenous testosterone bypasses normal feedback mechanisms 12.

This means attempting to lower SHBG to increase total testosterone from pellets is physiologically misguided. The solution is proper dosing of appropriate testosterone formulations, not SHBG manipulation.